

The present study was conducted on 40 subjects selected from the E.N.T. out patients clinic, Zagazig University Hospital. They were divided into 2 main groups:

Group A: that included 20 healthy control subjects, 10 females and 10 males.

Group B: that included 20 patients suffering from pure allergic rhinitis, 12 females and 8 males. The age of the patients was ranging from 10-47 years with an average of 27.5 years. This group was further subdivided into two subgroups: (B₁, B₂) each including 10 patients.

Table (1): Sex distribution of the patients of group B.

Sex	No. of patients	8
Females	12	60
Males	8	40
Total	20	100

Table (2): Age distribution of patients of group B.

Age group	No. of patients	8
10-	5	25
20-	7	35
30-	6	30
40-	2	10
Total	20	100

Mean age ±S.D.= 27.5 ±9.665

The results obtained from the studied Cases are represented as' follows:

Group A: Which consisted of twenty normal healthy control subjects. Those subjects were not suffering from anything abnormal in their nose. The results of IgE study of this group are shown in *Table (3)*.

Table (3): The level of IgE (IU/ml) in the nasal secretion of the subjects of the control group (Group A)

Case No.	IgE Level (IU/ml)
1	29.07
2	22.92
3	17.74
4	36.87
5	30.98
6	41.78
7	62.73
8	47.72
9	59.71
10	51.69
11	36.87
12	66.76
13	32.94
14	43.76
15	56.69
16	52.68
17	36.87
18	51.69
19	41.78
20	57.70
Mean	43.95
S.D.	13.54
S.E.	3.02

Range

17.74 to 66.76 IU/m1

Group B: Which consisted of 20 patients with pure allergic rhinitis. The results obtained from studying this group are classified into two main types: Clinical and Laboratory results.

Results of clinical studies:

The following tables (4-8) demonstrate the prevalence and variation in the symptoms of allergic rhinitis in the patients of group B.

Table (4): The prevelance of symptoms of allergic rhinitis in the patients before nasal challenge.

Symptoms	Severity	No. of patients	Prevalence
Sneezing	(+ + +)	18	90 %
Rhinorrhoae	(++)	15	75 %
Itching	(+ +)	10	50 %
Obstruction	(+++)	12	60 %

Table (5): The prevalence of symptoms of allergic rhinitis in the patients during the early phase of nasal challenge.

Symptoms	Severity	No. of patients	Prevalence
Sneezing	(+)	4	20 %
Rhinorrhoae	(+)	3	15 %
Itching	(+)	5	25 %
Obstruction	(+)	2	10 %

Table (6): The prevalence of symptoms of allergic rhinitis in the patients during the late phase of nasal challenge.

Symptoms	Severity	No. of patients	Prevalence
Sneezing	(+ + +)	19	95 %
Rhinorrhoae	(+ + +)	16	80 %
Itching	(+ + +)	17	85 %
Obstruction	(+ + +)	20	100 %

Table (7): The prevalence of symptoms of allergic rhinitis in the patients after topical use of steroids for two weeks before nasal challenge.

Symptoms	Severity	No. of patients	Prevalence
Sneezing	(+)	2	10 %
Rhinorrhoae	(+)	1	5 %
Itching	(+)	2	10 %
Obstruction	-	-	0 %

Table (θ): The prevalence of symptoms of allergic rhinitis in the patients after topical use of steroids for 3h. before nasal challenge.

Symptoms	Severity	No. of patients	Prevalence
Sneezing	(+)	3	15 %
Rhinorrhoae	(+)	2	10 %
Itching	(+)	2	10 %
Obstruction	(+)	1	5%

Results of 1gE determination using Behring ELISA photometer:

The following tables (9-12) show the level of IgE (IU/ml) in nasal secretions of the patients group.

Table (9): The level of IgE (IU/ml) in nasal secretions of patients of group B before nasal challenge.

Case No.	IgE Level (IU/ml)
1	72.80
2	82.02
3	70.78
4	83.31
5	75.82
6	61.73
7	82.02
8	85.89
9	107.3
10	98.36
11	100.0
12	142.0
13	114.5
14	75.82
15	118.1
16	114.5
17	105.4
18	194.4
19	155.4
20	109.1
Mean	102.46
S.D.	32.36
S.E.	7.23

Range

61.73 to 194.4

Table (10): The level of IgE (IU/ml) in nasal secretions of patients of group B after nasal challenge.

Case No.	IgE Level (IU/ml)
1	174.5
2	196.4
3	168.5
4	190.4
5	212.4
6	168.5
7	176.4
8	157.1
9	103.6
10	147.7
11	110.0
12	138.3
13	202.4
14	157.1
15	153.3
16	112.7
17	109.1
18	110.0
19	138.3
20	110.9
Mean	151.88
S.D.	34.54
S.E.	7.72

Range

103.6 to 212.4

Table (11): The level of IgE (IU/ml) in nasal secretions of patients of group B, after two weeks of topical use of steroids and nasal challenge.

Case No.	IgE Level (IU/ml)
1	45.74
2	30.98
3	72.80
4	50.70
5	90.14
6	63.74
7	35.89
8	29.07
9	44.75
10	67.77
Mean	53.158
S.D.	19.95
S.E.	6.30

Range 29.07 to 72.80

Table (12): The level of IgE (IU/mI) in nasal secretions of patients of group B2 after topical use of steroids for 3 hours before nasal challenge.

Case No.	IgE Level (IU/ml)
1	45.74
2	31.96
3	75.82
4	70.78
5	45.74
6	59.71
7	43.76
8	62.73
9	48.71
10	43.76
Mean	52.87
S.D.	13.798
S.E.	4.36

Range 31.96 to 70.78

Table (13) : Mean values, S.D. of IgE (IU/ml) in nasal secretions of control group (A) and patient group (B).

	Control group	Patient group	t	P
Mean	43.95	102.46	4.459	<0.001
S.D.	13.54	32.36		

This table shows a very high significant difference in IgE among patient group when compared with the control group.

Table (14) : Mean values, S.D. of IgE (IU/ml) in nasal secretions of control group B_1 and patient group B_2 .

	Group B1	Group B2	1	P
Mean	53.198	52.87	0.037	<0.05
S.D.	19.95	13.798		N.S.

This table shows that there is no significant difference between mean values of IgE in nasal secretions when measured after 3 hours and after two weeks of topical use of steroids.

Statistical Analysis

The statistical analysis for these results was done using the standard statistical methods:

1. Arithmetic Mean,

$$\bar{x} = \frac{x}{n}$$

Where X-The sum of individual observations.

n= The number of the observations.

2. Standard deviation:

$$8.D.=\sqrt{\frac{(x-\overline{x})^2}{n}}$$

3. Comparing two sample means: The t-test was used to test for the significance of the difference between two means.

$$\mathbf{S.D.=} \sqrt{\frac{\mathbf{\bar{X}}_1 - \mathbf{\bar{X}}_2}{\mathbf{S.D}_1^2} + \frac{\mathbf{S.D}_2^2}{\mathbf{n}_2}}$$

Where:

X₁=Arithmatic mean of sample₁
x₂=Arithmatic mean of sample₂
S.D₁=Standard deviation of sample₁
S.D₂=Standard deviation of sample₂
n₁=No. of cases in sample₁
n₂=No. of cases in sample₂

The probability (P) for the calculated values of (t) was obtained from statistical tables.